Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angieoedema
Biotech
Pharvaris oral hereditary angioedema med cuts attacks in phase 2
Patients taking Pharvaris’ preventative oral medicine for hereditary angioedema had an 84.5% reduction in monthly attacks during a phase 2 study.
Annalee Armstrong
Dec 6, 2023 10:18am
Pharvaris runs tox test to reverse clinical hold for HAE asset
Jan 9, 2023 10:42am
Catabasis Pharmaceuticals no more: Meet Astria Therapeutics
Sep 8, 2021 9:00am
KalVista hit with a clinical hold on 2nd asset
Apr 20, 2021 8:05am
Ionis' antisense drug curbs HAE attacks in phase 2
Mar 29, 2021 9:55am
Pharvaris nabs Shire exec as new CMO
Feb 7, 2020 9:22am